Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer - AXOAXI
- Conditions
- metastatic colorectal cancerTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2011-003137-33-FI
- Lead Sponsor
- Pia österlund and Helena Isoniemi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 100
Inclusion criteria
1.Patients with histologically confirmed diagnosis of CRC, chemotherapy naïve for metastatic disease (prior adjuvant chemotherapy more than 6 months previously for CRC allowed), who are scheduled to start first line chemotherapy for metastatic disease
2.Age ? 18
3.Measurable or evaluable metastatic disease
4.Performance status ECOG performance status 0-2
5.Life expectancy greater than 3 months
6.Thrombocytes ? 100’000/?l, neutrophils ? 1’500/µl, Aspartate amino transferase/Alanine amino transferase ? 2.5 ? Upper limit of normal (ULN) (= 5 ? ULN if liver metastases present), Alkaline phosphatase ? 2.5 ? ULN (= 5 ? ULN if liver metastases present), Serum bilirubin ? 1.5 ? ULN, Serum Creatinine ? 1.5 ? ULN, Urine dipstick of proteinuria <2+ (or U-Prot <100mg/dl). Patients discovered to have ?2+ proteinuria on dipstick urinalysis at baseline, must undergo a 24-hour urine collection and must have ? 1 g of protein/24 hr
7.Women of childbearing potential must have a negative serum pregnancy test done prior to the administration of bevacizumab. Patient and their partner should have adequate contraception up to at least 6 months after last treatment completion or the last drug dose, whatever happens first
8.Signed written informed consent according to ICH/GCP and the local regulations (approved by the Independent Ethics Committee [IEC]) will be obtained prior to any study specific screening procedures
9.Patient must be able to comply with the protocol
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion criteria
1.Prior treatment with first-line chemotherapy for metastatic CRC
2.Adjuvant treatment within 6 months
3.Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 0 (Patients must have recovered from any major surgery)
4.Near future planned radiotherapy for underlying disease (prior completed radiotherapy treatment allowed)
5.Clinical or radiological evidence of CNS metastases
6.Past or current history within the last 2 years of malignancies except for the indication under this study and curatively treated basal and squamous cell carcinoma of the skin or in-situ carcinoma of the cervix
7.Serious non-healing wound or ulcer
8.Evidence of bleeding diathesis or coagulopathy
9.Uncontrolled hypertension
10.Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (= 6 months), myocardial infarction (= 6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication
11.Treatment with any investigational drug within 30 days prior to enrolment
12.Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the treatment or patient at high risk from treatment complications
13.Chronic daily intake of aspirin (> 325 mg/day) or clopidogren (> 75 mg/day)
14.Pregnancy (positive serum pregnancy test) and lactation
15.Any other serious or uncontrolled illness which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: - PFS<br>- To assess overall resectability in patients with metastatic colorectal cancer, postoperative morbidity and outcomes after resection<br>;Secondary Objective: - To assess response rates according to RECIST criteria, failure free survival (TTF) and overall survival (OS)<br>- Quality of life according to 15D questionnaire<br>- To radiologically assess tumor density and morphology, and assess alternative radiologic response evaluation in comparison with RECIST response criteria<br>- Biomarker evaluation to measure plasma biomarkers, tumor blocks and DNA polymorphisms that may predict drug effects, safety, and clinical behavior of the tumor<br>;Primary end point(s): PFS, resectability rate
- Secondary Outcome Measures
Name Time Method Secondary end point(s): - response rates, failure free survival (TTF) and overall survival (OS)<br>- Quality of life stionnaire<br>- tumor density and morphology and alternative radiologic response evaluation<br>- Biomarker evaluation